Skip to main content
AREV Life Sciences Global Corp. logo

AREV Life Sciences Global Corp. — Investor Relations & Filings

Ticker · AREVF ISIN · CA04019J1093 CSE Manufacturing
Open in API
Filings indexed 155 across all filing types
Latest filing 2024-04-05 AGM Information
Country CA Canada
Listing CSE AREVF

About AREV Life Sciences Global Corp.

www.arevlifesciences.com

AREV Life Sciences Global Corp. is an early-stage life science discovery and nutra-ceutical company specializing in the development and commercialization of health and wellness solutions. The core business involves the production and sale of functional compounds and premium ingredients, which are derived using proprietary extraction systems. AREV focuses its research and development efforts on novel therapeutic approaches targeting human nutrition, malnutrition, and pandemic diseases. The company also engages in early-stage commercial research programs, including the study of cannabinoids.

Recent filings

Filing Released Lang Actions
Management information circular - English.pdf
AGM Information Classification · 100% confidence The document is titled 'Information Circular' and is related to the solicitation of proxies for the Annual General Meeting (AGM) of shareholders. It contains detailed proxy information, voting procedures, record dates, and information about shareholders and directors. It does not contain financial statements or results but is clearly a document prepared for the AGM to inform shareholders about the meeting and voting process. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document length is substantial (15,000 characters), indicating it is the full circular, not just an announcement. Therefore, the correct classification is AGM-R with high confidence.
2024-04-05 English
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a Financial Statement Request Form from AREV LIFE SCIENCES GLOBAL CORP. It is a form for shareholders or beneficial owners to request copies of the company's annual or quarterly financial statements and MD&A. The document does not contain any financial data, results, or analysis itself, nor does it announce or present any financial report. It is essentially a communication related to the distribution of financial reports, not the reports themselves. Given its nature as a request form and the absence of substantive financial content, it does not fit into categories like Annual Report (10-K), Interim Report (IR), or Management Reports (MDA). It is also not an announcement of a report publication but a request for receiving reports. The best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory communications that do not fit other categories.
2024-04-05 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Form of Proxy for the Annual General Meeting (AGM) of Arev Life Sciences Global Corp. It includes instructions for appointing proxyholders, voting on director elections, appointment of auditors, approval of stock option plans, and other resolutions to be considered at the AGM. It is not the actual AGM presentation or materials but a proxy solicitation form for voting at the AGM. Proxy forms are classified under Proxy Solicitation & Information Statement (PSI). The document length (8840 characters) and content confirm it is a proxy solicitation form, not an announcement or report publication. Therefore, the correct classification is PSI.
2024-04-05 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release from AREV Life Sciences Global Corp. announcing significant corporate progress during a trading suspension period. It discusses the completion of audit and financial reporting processes, relocation of facilities, integration of AI technology, and ongoing preclinical studies. The document does not contain detailed financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, governance report, or any other specific regulatory filing. The content is primarily an update on corporate developments and operational progress, typical of a Capital/Financing Update (CAP) or general corporate progress announcement. Given the focus on audit completion and regulatory compliance, but without the full audit report attached, and the emphasis on corporate progress and operational updates, the best fit is Capital/Financing Update (CAP). The document length (7674 characters) and content support this classification with high confidence.
2024-02-06 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management's Discussion and Analysis for the Nine Months Ended September 30, 2023' and dated December 8, 2023. It contains detailed narrative about the company's business, operations, forward-looking statements, and financial condition for the nine-month interim period ending September 30, 2023. It references condensed consolidated interim financial statements prepared under IFRS for the nine months ended September 30, 2023, and discusses business segments, product development, and corporate structure. The length is substantial (15,000 characters) and contains substantive financial and operational analysis, not just an announcement or certification. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive analysis. Therefore, the correct classification is IR with high confidence.
2023-12-08 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the CFO of AREV Life Sciences Global Corp. regarding the interim financial report and interim MD&A for the period ended September 30, 2023. It is a Venture Issuer Basic Certificate under Form 52-109FV2, which certifies the review and fair presentation of the interim filings but does not contain the actual financial data or detailed interim report itself. The document is primarily an officer certification letter, not the interim report or MD&A. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (2986 characters) and it does not contain substantive financial data or analysis, only the certification statement. Therefore, the correct classification is Regulatory Filings (RNS).
2023-12-08 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.